MNK - Mallinckrodt plc

NYSE - NYSE Delayed Price. Currency in USD
8.20
-0.22 (-2.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.42
Open8.34
Bid0.00 x 800
Ask0.00 x 1800
Day's Range8.13 - 8.45
52 Week Range8.00 - 36.65
Volume2,232,043
Avg. Volume3,190,169
Market Cap669.316M
Beta (3Y Monthly)2.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report?
    Zacks2 days ago

    Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report?

    Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • How St. Louis stocks compare with stocks nationally
    American City Business Journals7 days ago

    How St. Louis stocks compare with stocks nationally

    Stocks have done so well nationally this year that the relatively few St. Louis companies have had a hard time keeping pace.

  • Mallinckrodt (MNK) Outpaces Stock Market Gains: What You Should Know
    Zacks19 days ago

    Mallinckrodt (MNK) Outpaces Stock Market Gains: What You Should Know

    Mallinckrodt (MNK) closed the most recent trading day at $9.18, moving +1.89% from the previous trading session.

  • MarketWatch22 days ago

    Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium

    Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc.'s deal to buy Allergan PLC for a 45% premium. The SPDR S&P Pharmaceuticals ETF rallied 2.2% ahead of the open. Besides the 31% jump in Allergan's stock, among other shares seeing nice gains in the premarket, Mylan N.V. rose 2.7%, Endo International PLC climbed 4.5%, Theravance Biopharma Inc. hiked up 4.2%, Mallinckrodt PLC tacked on 2.7% and Perrigo Co. PLC gained 2.2%. Meanwhile, Medicines Co.'s stock shed 4.6%, after the company announced late Monday the public offering of $150 million worth of common stock. The pharmaceuticals ETF has lost 7.7% over the past three months through Monday, while the S&P 500 has gained 5.3%.

  • Barrons.com23 days ago

    The U.S. Gets Hundreds of Millions From Big Pharma in Co-Pay Settlements

    The federal government has secured almost $850 million in settlements from the pharmaceutical industry since a Barron’s investigation revealed how companies used charities in ways that undermined efforts to hold back skyrocketing drug prices.

  • Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
    Zackslast month

    Mallinckrodt Presents Encouraging Data on Acthar Gel for RA

    Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.

  • Markitlast month

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    Mallinckrodt Plc NYSE:MNKView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for MNK with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MNK totaled $9.22 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Mallinckrodt Down After Agreement with DOJ for Litigation
    Zackslast month

    Mallinckrodt Down After Agreement with DOJ for Litigation

    Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.

  • Why Is Mallinckrodt (MNK) Down 47.4% Since Last Earnings Report?
    Zackslast month

    Why Is Mallinckrodt (MNK) Down 47.4% Since Last Earnings Report?

    Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Benzingalast month

    Mallinckrodt Agrees To Pay $15.4M In DOJ Settlement Over Acthar Subsidies

    The Justice Department accused Questcor in the years 2010-2014 of using a patient charity as a means of improperly subsidizing Medicare copayments in order to continue raising prices of H.P. Acthar gel, according to Reuters.

  • MarketWatchlast month

    Mallinckrodt's stock falls after it expects to pay more than $15 million to resolve DOJ investigation

    Shares of Mallinckrodt PLC dropped 2.4% in afternoon trade Wednesday, after the biopharmaceutical company said it reached an agreement in principle with the U.D. Department of Justice to resolve the investigation into the legacy sales and marketing activities of Questcor, which Mallinckrodt acquired in August 2014. Mallinckrodt expects to pay $15.4 million in the settlement, which will not contain any admission of wrongdoing. Meanwhile, the company intends to "vigorously defend" itself against any wrongdoing, with respect to the DOJ's newly filed allegations that Questcor's charitable activities between 2010 and 2014 violated the False Claims Act and the Anti-Kickback Statute. The stock has tumbled 58% over the past three months, while the S&P 500 has gained 1.1%.

  • Barrons.com2 months ago

    Mallinckrodt Stock is Falling Because the Wheels Might ‘Finally Come Off’

    PiperJaffray analyst David Amsellem downgraded the company from Overweight to Neutral, writing that developments last week had blown his bull thesis “to smithereens.”

  • Cara Shares Up on Positive Phase III Data for Itchiness Drug
    Zacks2 months ago

    Cara Shares Up on Positive Phase III Data for Itchiness Drug

    Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.

  • Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down
    Zacks2 months ago

    Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

    Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.

  • Reuters2 months ago

    Mallinckrodt's Amitiza to stay with branded business after spin-off

    The company had said in December it was open to a sale of the generics business or would spin it off in the second half of 2019. It had said Amitiza would be part of the spun-off unit. Shares of Mallinckrodt were down 6.3% in noon trading, as concerns related to its Acthar gel continued to weigh on the stock.

  • TheStreet.com2 months ago

    Mallinckrodt Rises After Announcing Plans to Spin Off Specialty Generics Unit

    The stock was rising 5.49% in premarket trading, only to fall 1.77% to $9.44 in regular hours. Mallinckrodt will focus on specialty branded pharmaceuticals while Sonorant will focus on specialty generic products and APIs1 manufacturing. "I am very pleased with the highly experienced management team we have assembled," said Matthew Harbaugh, president of Mallinckrodt's specialty generics business.

  • Reuters2 months ago

    Mallinckrodt to spin-off generics business, keep constipation drug

    Mallinckrodt Plc said on Tuesday it would spin-off its specialty generics unit and rename the remaining specialty branded drugs business to Sonorant Therapeutics Plc. Sonorant will keep constipation medicine Amitiza, Mallinckrodt said. The company had said in December it was open to a sale of the generics business or would spin it off in second half of 2019.

  • Cramer Remix: Why Chipotle's downgrade is misguided
    CNBC2 months ago

    Cramer Remix: Why Chipotle's downgrade is misguided

    Jim Cramer explains why worries at the restaurant chain may be off-base.

  • Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS
    Zacks2 months ago

    Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS

    Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.

  • Benzinga2 months ago

    Mallinckrodt Slumps After Filing Acthar Lawsuit, But BMO Says It Can Take The Hit

    Mallinckrodt PLC (NYSE: MNK) announced Tuesday that it filed a lawsuit against the Department of Health and Human Services and Centers for Medicare and Medicaid Services, challenging the federal government's decision to have the company change the base date average manufacturer price used to calculate Medicaid drug rebates for Acthar gel. The news of the lawsuit is disappointing, as it could potentially eliminate Acthar's Medicaid sales, Nachman said in a Tuesday note.

  • Barrons.com2 months ago

    Mallinckrodt Stock Could Take Another Plunge, Analyst Says

    The drugmaker is facing headwinds from opioid lawsuits and a decision by the federal government to cut reimbursements for a key product.

  • Mallinckrodt shares crater after drug maker files suit to protect Medicaid patient access to Acthar
    MarketWatch2 months ago

    Mallinckrodt shares crater after drug maker files suit to protect Medicaid patient access to Acthar

    Mallinckrodt PLC shares tumbles after the drug company says it has filed suit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services to protect Medicaid patient access to its Acthar gel.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MNK earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 Mallinckrodt Plc Earnings Call